Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ocrelizumab (IDC-2403) is a humanized monoclonal antibody directed against CD20 for the treatment of multiple sclerosis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | 232 € | In Stock | |
5 mg | 614 € | In Stock | |
10 mg | 986 € | In Stock | |
25 mg | 1.676 € | In Stock | |
50 mg | 2.517 € | In Stock |
Description | Ocrelizumab (IDC-2403) is a humanized monoclonal antibody directed against CD20 for the treatment of multiple sclerosis. |
In vivo | In a mouse model of multiple sclerosis, Ocrelizumab, administered subcutaneously or intravenously at a dose of 7.5 mg/kg once daily for 18 days, induced B-cell depletion by an antibody-dependent cellular cytotoxicity (ADCC) mechanism to inhibit lesions. In C57BL/6 mice, Ocrelizumab administered intravenously at a dose of 50 μg on days 7, 14, and 21 significantly reduced B and T cells in the blood, lymph nodes, and spleen.[1][2] |
Alias | IDC-2403, IDC2403 |
Molecular Weight | 145.5 kDa |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.